Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Consulting agrmnt
Appointed director
Aptevo Therapeutics Inc. (APVO) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/10/2023 8-K Quarterly results
08/03/2023 424B4 Form 424B4 - Prospectus [Rule 424(b)(4)]:
08/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
08/01/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
07/18/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
07/14/2023 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
06/30/2023 S-1 Form S-1 - General form for registration of securities under the Securities Act of 1933:
06/02/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
04/19/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/18/2023 ARS Form ARS - Annual Report to Security Holders:
04/18/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/30/2023 10-K Annual Report for the period ended December 31, 2022
03/30/2023 8-K Quarterly results
03/30/2023 8-K Quarterly results
03/07/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/13/2023 8-K Quarterly results
01/09/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors New PD-L1 x CD40 Candidate Built on Proprietary ADAPTIRä Platform, Enters Pre-Clinical Pipeline"
12/12/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia Aptevo Therapeutics Plans a Phase 2 Trial in 2H23 in Frontline and Relapsed/Refractory Patients who are Venetoclax Treatment Naïve"
11/10/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/10/2022 8-K Quarterly results
Docs: "Updated Results from a Phase 1study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 ADAPTIR™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome” will be presented on Sunday, December 11, 2022 from 6:00 PM-8:00 PM Central time"
11/04/2022 8-K Quarterly results
09/19/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a “May Proceed” Notification for the ALG.APV-527 IND Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types"
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/09/2022 8-K Quarterly results
06/08/2022 8-K Quarterly results
06/07/2022 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
06/07/2022 8-K Quarterly results
05/31/2022 8-K Quarterly results
05/12/2022 10-Q Quarterly Report for the period ended March 31, 2022
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy